# Trial of Romidepsin and Bortezomib for Multiple Myeloma

> **NCT00765102** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT00765102
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-01
- **Primary completion:** 2010-03-01
- **Final completion:** 2010-03-01
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** There was a change in the Sponsor's research strategy; safety concerns were not a factor.
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765102, "Trial of Romidepsin and Bortezomib for Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00765102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*